Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Silence Therapeutics PLC Sponsored ADR SLN

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
789.30
Revenue
0.84
Net Income
(59.95)
Free Cash Flow
(42.26)
Net Debt
(72.05)
Current Ratio
7.42
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
686.88
P/B ratio
14.98
Past 5Y EPS Growth
0.35%
This Y EPS Growth
22.90%
Next Y EPS Growth
(19.71%)
Next 5Y EPS Growth
(1.68%)
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 68.79 147.33 85.11 72.05
Receivables 22.73 25.37 22.01 9.29
Inventory — — — —
Other 11.63 14.66 11.54 12.94
103.15 187.37 118.66 94.28
2023 2024 2025 Q'26
Payables 15.54 16.40 13.36 12.61
ST’ Debt — — — —
Other 6.57 0.31 0.17 —
22.34 16.82 13.61 12.71
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 0.42 — — —
—
’25 0.14 0.22 0.16 0.03
0.56
’24 15.70 0.76 1.50 25.31
43.26
’23 13.82 11.40 3.54 2.88
31.64
’22 7.68 4.57 3.97 5.43
21.65
’21 — 11.27 4.05 12.10
17.07
’20 — 1.78 — 7.75
7.04
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (15.60) 1.52 — —
—
’25 (12.31) (21.78) (10.89) (17.29)
(62.27)
’24 (9.14) (5.41) (25.61) (27.48)
(67.64)
’23 (9.30) (19.01) (6.48) (14.67)
(49.46)
’22 (19.29) (9.14) (9.32) (18.48)
(56.22)
’21 — 19.48 (7.91) (13.61)
9.36
’20 — 1.40 — (13.84)
(13.84)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (15.60) 1.52 — —
—
’25 (12.31) (21.83) (10.89) (17.29)
(62.33)
’24 (9.14) (5.49) (25.67) (27.54)
(67.85)
’23 (9.34) (44.88) (6.51) (14.67)
(49.52)
’22 (19.36) (9.18) (9.36) (18.86)
(56.77)
’21 — 18.85 (8.29) (13.61)
7.52
’20 — 1.40 — (14.49)
(14.49)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.32) (0.26) — —
—
’25 (0.60) (0.57) (0.45) (0.25)
(1.89)
’24 (0.05) (0.42) (0.75) 0.27
(0.99)
’23 (0.35) (0.36) (0.28) (0.47)
(1.45)
’22 (0.35) (0.50) (0.25) (0.46)
(1.56)
’21 — (0.32) (0.46) (0.30)
(1.83)
’20 — (0.17) — (0.36)
(0.40)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.6
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡ ‡‡‡‡ 7.80 4.55 5.81 1.97 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡ 24.66 18.95 27.72 8.08 — — —
High Price
— — — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 122 109 116 88 — — —
Employees
‡‡‡ ‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.18 0.29 0.37 0.01 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 21.65 31.64 43.26 0.56 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 37.83% 59.34% 72.70% 61.54% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (58.59) (53.27) (44.46) (88.60) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (270.66%) (168.35%) (102.79%) (15,849.91%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (58.59) (54.23) (45.31) (88.61) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.60 0.62 0.59 0.56 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.67 0.85 0.94 0.01 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ (1.56) (1.45) (0.99) (1.89) ‡‡‡‡‡ — —
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.75) (1.33) (1.46) (1.32) — — —
Cash Flow/Sh
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.02) 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.76) (1.33) (1.47) (1.32) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.85 0.59 2.90 1.32 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 32.20 37.09 46.25 47.23 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ — ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡ ‡‡‡ — ‡‡‡ ‡‡‡ ‡‡‡‡‡ 21.85 21.74 7.36 513.72 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.32 31.29 2.37 4.61 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡ ‡‡‡ — ‡‡‡ ‡‡‡ ‡‡‡‡‡ 17.81 19.58 3.96 362.12 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (6.84) (12.51) (2.52) (3.25) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (56.22) (49.46) (67.64) (62.27) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.54) (0.06) (0.21) (0.05) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (56.77) (49.52) (67.85) (62.33) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 92.45 80.82 170.54 105.05 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.65 0.12 — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (87.35) (68.67) (147.33) (85.11) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 27.30 21.99 134.02 62.30 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (37.76%) (42.97%) (28.13%) (53.05%) — — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (256.66%) (220.02%) (58.08%) (90.27%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Silence Therapeutics PLC (SLN) has engineered a remarkable revenue trajectory, surging 514% from $7.0 million in 2020 to $43.3 million in 2024, propelled by milestone payments from AstraZeneca’s $100 million SLN360 deal and other partnerships leveraging its mRNAi GOLD platform. Revenue per employee tripled to $372,914, with gross margins climbing to 73%, signaling operational efficiency amid modest headcount growth. Yet, this lumpiness foreshadows an 81% plunge to $8.0 million in 2025, echoing biotech cycles where windfalls fade without recurring sales.

Despite narrowing losses—EBT margin improving to -1.0% and ROE to -58%—cash flows remain volatile, with 2024 free cash flow per share at -$1.47 amid pipeline investments, supported by a $170 million working capital buffer. The stock, trading near multi-year lows after an 80%+ drawdown from 2021 peaks despite tripling revenues, sports a compressed 7x price-to-sales multiple and lags analyst means by 460%, implying explosive upside potential of up to 1580% on Phase 2 catalysts for SLN360 and SLN124.

Analyst consensus projects deeper 2025 losses at $101 million but hinges optimism on cardiovascular pipeline successes amid rising disease prevalence, with historical RNAi peers like Alnylam offering precedents for blockbuster re-ratings. Risks loom from clinical setbacks, dilution, and funding droughts, positioning SLN as a high-beta bet for risk-tolerant quants—full analysis unpacks probabilistic scenarios and strategic entry points.

Read full commentary →

Silence Therapeutics PLC Sponsored ADR (SLN) Latest News

News by impact score

Fine-tune

14 Aug

3 , 4:55 PM
Silence Therapeutics closed an upsized public offering of ADSs with full exercise of the underwriters’ option to purchase additional shares. The capital raise supplies cash for operations but increases share count via dilution with potential short-term price pressure.

11 Aug

4 , 11:05 AM
Morgan Stanley states Silence Therapeutics' Divesiran data supports best-in-class potential. Positive analyst view on core drug data can lift investor sentiment and share trajectory for Silence Therapeutics.

4 www.marketbeat.com, 1:01 AM
Silence Therapeutics’ Divesiran met Phase II endpoints, clearing the path for a Phase III PV trial. Phase II success and Phase III setup represent a major clinical milestone that can materially shift pipeline value and investor sentiment.

3 , 11:20 PM
Silence Therapeutics prices upsized $175 million underwritten public offering of common stock. The capital raise bolsters cash reserves for pipeline development but dilutes existing shares.

10 Aug

4 , 4:01 PM
Silence Therapeutics announces proposed public offering of $150 million American Depositary Shares. Proposed $150 million ADS offering dilutes shares while injecting major capital for operations.

4 , 7:30 AM
Silence Therapeutics announced positive topline results from Phase 2 SANRECO trial of divesiran in polycythemia vera, supporting potential best-in-class profile. Positive Phase 2 results for divesiran advance lead asset and strengthen long-term growth prospects.

3 , 7:15 AM
Silence Therapeutics reported its second quarter 2026 financial results and business updates. Quarterly financial reports deliver performance updates that can shift short-term investor views and stock movement without major strategic shifts.

9 Aug

3 , 5:00 PM
Silence Therapeutics will host a conference call and webcast to discuss topline results from its Phase 2 SANRECO trial of Divesiran in Polycythemia Vera. Phase 2 trial data readout represents clinical progress that can moderately shift investor views on the company's pipeline.

30 Jun

3 , 9:06 AM
Silence Therapeutics plc (SLN) received an Overweight rating initiation as the analyst emphasized strong potential in its siRNA pipeline. Analyst Overweight initiation citing siRNA pipeline potential can moderately lift near-term investor sentiment and share performance.

25 Jun

4 Zacks, 7:48 AM
SLN shares rose 26.0% in heavy trading, prompting questions on whether momentum will produce additional gains. Sharp 26% price surge reflects major market reaction capable of shifting near-term trajectory and sentiment.

17 Jun

3 , 11:16 AM
Silence Therapeutics builds divesiran case for polycythemia vera treatment by emphasizing fewer required blood draws as key advantage. Divesiran development update for polycythemia vera may moderately affect Silence Therapeutics competitive positioning and investor sentiment.

11 Jun

4 , 7:30 AM
Silence Therapeutics presented follow-up data at EHA 2026 demonstrating durable efficacy and potential best-in-class profile for Divesiran in Polycythemia Vera. Positive Divesiran efficacy data strengthens pipeline value and investor outlook for SLN.

16 Apr

4 Zacks, 8:50 AM
Silence Therapeutics (SLN) stock surged 19.0%, prompting analysis on whether further upside remains amid positive momentum. 19% stock surge reflects significant market enthusiasm likely to influence investor sentiment and trajectory.

5 Mar

4 Business Wire, 7:30 AM
Silence Therapeutics PLC Sponsored ADR (SLN) highlights recent business achievements and reports fourth quarter and full year 2025 financial results. Financial results and business achievements directly impact financial performance, pipeline progress, and investor sentiment for biotech SLN.

3 Zacks, 9:55 AM
Wall Street analysts forecast a 467.47% upside for Silence Therapeutics (SLN) stock, questioning if such gains are realistic amid its clinical pipeline and market challenges. Analyst upside predictions of 467.47% can moderately boost market sentiment and short-term trading interest without altering core operations.

12 Jan

3 MT Newswires, 11:19 AM
European equities traded in the US as American Depositary Receipts (ADRs) saw an increase in trading on Monday, with Silence Therapeutics PLC Sponsored ADR (SLN) being among the notable performers. The rise in ADRs reflects a broader trend in the market, indicating positive investor sentiment towards European companies listed in the US. This uptick may suggest growing interest and confidence in the potential of these companies, including Silence Therapeutics, as they navigate the evolving market landscape. The increase in ADR trading indicates a moderately noticeable influence on market sentiment towards Silence Therapeutics and its potential performance.

21 Dec

4 Simply Wall St., 7:14 AM
Silence Therapeutics PLC insiders hold a significant 35% ownership stake in the company, indicating their strong commitment and potential influence over its strategic direction. This level of insider ownership often aligns the interests of management with those of shareholders, potentially leading to more effective decision-making and long-term value creation. Investors may view this as a positive signal regarding the company's future prospects and governance. High insider ownership can significantly impact investor sentiment and company strategy.

15 Dec

4 , 8:13 AM
Silence Therapeutics PLC has announced significant leadership changes, including the appointment of a new Chief Executive Officer and Chief Financial Officer. These changes are part of the company's strategy to enhance its operational capabilities and drive future growth. The new leadership team is expected to bring fresh perspectives and expertise to the organization, aiming to strengthen its position in the biotechnology sector. Leadership changes at the executive level can significantly impact strategic direction and operational effectiveness, influencing investor sentiment and company performance.

30 Nov

3 , 7:23 AM
An insider at Silence Therapeutics PLC increased their stake in the company by 15% over the past year, indicating potential confidence in the company's future performance and prospects. Insider buying can signal confidence in the company's future, but the overall impact on performance is expected to be limited.

9 Nov

3 Simply Wall St.Simply Wall St.Simply Wall St., 7:10 AM
Analysts have significantly reduced their estimates for Silence Therapeutics PLC (NASDAQ: SLN), indicating a potential downturn in expected performance. This adjustment reflects concerns about the company's future financial outlook and market position, which may impact investor sentiment and stock performance. Analysts' substantial estimate cuts suggest a moderately noticeable influence on the company's financial performance and market perception.

6 Nov

4 Business WireMT NewswiresGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.com, 7:30 AM
Silence Therapeutics PLC reported its financial results for the third quarter of 2025, highlighting key business developments and financial metrics. The company showcased advancements in its therapeutic pipeline and strategic initiatives aimed at enhancing its market position. Financial performance indicators reflected ongoing investments in research and development, with a focus on expanding its product offerings and addressing unmet medical needs. The report emphasized the company's commitment to innovation and growth in the biopharmaceutical sector. Significant advancements in the therapeutic pipeline and strategic initiatives are likely to impact the company's future performance and market sentiment.

23 Oct

4 Business Wire, 7:30 AM
Silence Therapeutics PLC has completed enrollment in its Phase 2 SANRECO study of Divesiran, a treatment for Polycythemia Vera (PV). This milestone marks a significant step in the clinical development of Divesiran, which aims to address the unmet medical needs of patients with PV. The study will evaluate the safety and efficacy of the drug in this patient population. Completion of enrollment in a Phase 2 study for a treatment targeting a specific condition can significantly influence future market performance and investor sentiment.

17 Oct

4 Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St., 9:45 AM
Silence Therapeutics PLC is focusing on advancing its RNAi therapeutics pipeline, with a strong emphasis on its lead candidate, SLN124, aimed at treating beta-thalassemia and other blood disorders. The company is also exploring partnerships to enhance its research capabilities and expand its market reach. Recent financial results indicate a solid cash position, supporting its growth plans. However, challenges such as competition and regulatory hurdles remain. Investors are keenly watching the company's strategic moves and product development progress. Significant advancements in the RNAi pipeline and potential partnerships could greatly influence the company's growth trajectory and market position.

6 Oct

3 MT Newswires, 11:00 AM
European equities traded in the US as American Depositary Receipts (ADRs) saw an increase in trading on Monday. Silence Therapeutics PLC Sponsored ADR (SLN) was among the companies benefiting from this trend, reflecting a broader positive sentiment in the market for European stocks listed in the US. Investors showed renewed interest in these ADRs, indicating potential growth opportunities for companies like Silence Therapeutics. Increased trading activity in ADRs may enhance market sentiment and visibility for Silence Therapeutics, potentially influencing its financial performance.

8 Sep

3 MT Newswires, 11:08 AM
European equities traded in the US as American Depositary Receipts (ADRs) saw an increase in trading on Monday, with Silence Therapeutics PLC Sponsored ADR (SLN) being among the notable performers. The rise in ADRs reflects a broader trend in the market, indicating positive investor sentiment towards European companies listed in the US. This uptick may suggest growing interest in international equities and could impact trading volumes and valuations for companies like Silence Therapeutics. The increase in ADR trading indicates a moderately noticeable influence on market sentiment and could affect Silence Therapeutics' financial performance.

12 Aug

3 , 6:28 AM
Analysts have revised their estimates for Silence Therapeutics PLC following the company's second-quarter results. The updates reflect changes in financial projections and expectations regarding the company's performance in the biotechnology sector. Investors are closely monitoring these adjustments as they may influence market sentiment and the stock's trajectory. Revisions in analyst estimates indicate a moderately noticeable influence on the company's financial performance and market positioning.

7 Aug

3 , 7:30 AM
Silence Therapeutics PLC reported its financial results for the second quarter of 2025, highlighting key business developments and financial metrics. The company showcased advancements in its pipeline and strategic initiatives aimed at enhancing its market position. Financial performance indicators reflected ongoing efforts to drive growth and innovation within the biotechnology sector. Recent business highlights and financial results indicate moderate influence on the company's trajectory and market sentiment.

9 Jul

3 , 9:16 AM
Institutional ownership in Silence Therapeutics PLC (NASDAQ: SLN) has reached 39%, indicating significant interest from institutional investors. This level of ownership may reflect confidence in the company's potential and could influence future market performance. Increased institutional ownership may moderately influence investor sentiment and market performance.

12 Jun

4 Business Wire, 4:01 PM
Silence Therapeutics presented additional Phase 1 data for divesiran, a potential first-in-class siRNA treatment for polycythemia vera (PV), at the EHA 2025 Annual Meeting. The data showed that divesiran effectively maintained hematocrit levels and reduced the need for phlebotomies in patients. The SANRECO Phase 2 study has exceeded 50% enrollment and is on track for completion by the end of 2025. Divesiran demonstrated a favorable safety profile and improved iron deficiency without altering white blood cell counts. Silence Therapeutics aims to address the unmet medical need in PV treatment, as current therapies do not specifically target red blood cells and hematocrit. The promising Phase 1 data and significant enrollment progress in the Phase 2 study indicate a potential breakthrough in PV treatment, likely impacting the company's future performance.

6 Jun

4 Zacks, 9:55 AM
Silence Therapeutics PLC Sponsored ADR (SLN) shares have risen 52% recently, closing at $5.41, with analysts projecting a mean price target of $35.50, suggesting a potential upside of 556.2%. The estimates show a standard deviation of $23.86, indicating variability, with the lowest target at $3 (44.6% decline) and the highest at $75 (1286.3% increase). Analysts have revised earnings estimates upward, contributing to a Zacks Rank #2 (Buy), indicating strong potential for stock price movement. However, reliance solely on price targets is cautioned against, as they can be misleading due to analysts' business incentives. Analysts' upward revisions in earnings estimates and strong consensus suggest significant potential for stock price movement.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us